theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Radiation Oncology

HER2-low   

Questions discussed in this category


What are your top takeaways in Breast Cancer from ESMO 2024?
4 Answers available

Can trastuzumab deruxtecan be continued during radiation?
The patient has extensive disease, and requires palliative radiation to the scapular area (proximal to the brachial plexus) in a region overlapping wi...
1 Answer available
2170015830


Papers discussed in this category


The New England journal of medicine, 2024 Sep 15
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

Nature medicine, 2024 Sep 13
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Oct 21
A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial.

The New England journal of medicine, 2024 Sep 15
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.

Related Topics in Radiation Oncology

  • Lung Cancer
  • Workload
  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Gynecologic Oncology
  • Palliation
  • Neuro-Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers

Copyright © 2025 theMednet
All Rights Reserved.